Hot pre-market trades in US stocks: Cyabra is down 9.62% in pre-market trading, with no significant news but showing volatility. What is driving the market sentiment?

Pre-market Hot Trades in US Stocks Cyabra, down 9.62% in pre-market trading, has no significant news recently. The trading is active with clear capital flows, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. Top Gainers in Pre-market US Stocks Apellis Pharma up 139.67% in pre-market trading. Based on recent news, On March 31, Boehringer Ingelheim announced the acquisition of Apellis Pharmaceuticals, causing its stock price to surge by 140%. Boehringer will acquire Apellis Pharmaceuticals for $41 per share in cash plus CVR (contingent value rights), which triggered a strong market reaction and significantly boosted Apellis' stock price. On March 31, Bloomberg reported that Boehringer will acquire Apellis Pharmaceuticals for $41 per share in cash plus CVR, further confirming the details of this major transaction and enhancing market confidence, leading to a spike in the stock price. No other significant news recently. The pharmaceutical industry has seen frequent M&A activity, and market sentiment is high. Hitek Global Inc. up 102.50% in pre-market trading. Based on recent news, On March 27, Hitek Global Inc. announced a targeted issuance of $3 million in stock. The company plans to sell 100 million shares of Class A stock to certain institutional investors at a price of $0.03 per share, expecting to complete the issuance by March 30. This news triggered a positive market reaction, significantly boosting the stock price. On March 27, the company disclosed that it had signed a securities purchase agreement with specific entities, demonstrating its commitment to expanding business and services in the technology sector. This move enhanced investor confidence in the company's future development, further driving up the stock price. On March 27, the company reminded investors in an announcement that actual results may differ significantly from expectations and encouraged investors to review other factors that may affect future outcomes. Nevertheless, the market's positive reaction to the company's expansion plans still dominated the stock price trend. The technology sector has performed strongly recently, and investor sentiment is high. Centessa up 49.71% in pre-market trading. Based on recent key news: On March 31, Eli Lilly announced it will acquire Centessa Pharmaceuticals for $38 per share plus CVR. This news drove Centessa ADR up 45%, showing a positive market reaction to the deal. Source: Bloomberg On March 31, Eli Lilly plans to acquire Centessa Pharmaceuticals for approximately $6.3 billion to advance treatments for sleep-wake disorders. This move is seen as a significant positive for Centessa's future development, further boosting the stock price. Source: Reuters On March 31, after the news of Eli Lilly's planned acquisition of Centessa was released, Centessa's stock price surged significantly, reflecting investors' optimistic expectations for the deal. Source: Zhitong Finance. The pharmaceutical industry is experiencing frequent merger and acquisition activities, attracting high market attention